Shetal N. Shah MD, Presenter: Nothing to Disclose

Amit Gupta MBBS,DMRD, Abstract Co-Author: Nothing to Disclose

Sankaran Shrikanthan MD, Abstract Co-Author: Nothing to Disclose

Amanjit Singh Gill MD, Abstract Co-Author: Nothing to Disclose

Baljendra S. Kapoor MBBS, Abstract Co-Author: Consultant, Terumo Corporation

Shyam Srinivas MD, PhD, Abstract Co-Author: Nothing to Disclose

1) Illustrate a multidisciplinary treatment schema with emphasis on various trans-catheter treatments available requiring the concurrent use of PET/CT in unresectable liver cancer (ULC); 2) Define the specific roles of FDG and Yittrium-90 PET/CT prior to, during and following vascular therapy for ULC.

Functional imaging has an established role in management of liver cancer. Beyond its use in initial staging of liver cancers, FDG PET/CT is used for pre-transcatheter therapy planning for ULC by helping localize lesions and quantify tumor burden. Immediate post-therapy Yittrium-90 PET/CT scan may be performed to ascertain appropriate radiomicrosphere distribution and estimate lesion radiation dose. A subsequent  FDG PET/CT is essential in assessing therapy response and restaging disease.

Trans-catheter therapy for unresectable liver cancer is robust treatment option in patients with unresectable liver cancer. PET/CT imaging using FDG and Y-90 has a crucial role prior to, during and after therapy to define disease extent, quantify tumor burden, confirm radiomicrosphere distribution and assess therapy response.

Shah, S, Gupta, A, Shrikanthan, S, Gill, A, Kapoor, B, Srinivas, S, Emerging Role of FDG and Yittrium-90 PET/CT in Transcatheter Treatment of Unresectable Liver Cancer.  Radiological Society of North America 2011 Scientific Assembly and Annual Meeting, November 26 - December 2, 2011 ,Chicago IL. http://archive.rsna.org/2011/11013984.html